BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byun Y, Han Y, Kang JS, Choi YJ, Kim H, Kwon W, Kim SW, Oh DY, Lee SH, Ryu JK, Kim YT, Jang JY. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 2019;26:416-25. [PMID: 31218836 DOI: 10.1002/jhbp.648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6-13. [PMID: 32021953 DOI: 10.1002/ags3.12295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
2 Yamada S, Yokoyama Y, Sonohara F, Yamaguchi J, Takami H, Hayashi M, Onoe S, Fujii T, Nagino M, Kodera Y. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preoperative therapy. J Hepatobiliary Pancreat Sci 2020;27:487-95. [PMID: 32359199 DOI: 10.1002/jhbp.748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Yun W, Kwon W, Han Y, Sohn HJ, Kim HS, Lee M, Kim H, Thomas AS, Kluger MD, Jang J. Can Surgical Resection of Metastatic Lesions Be Beneficial to Pancreatic Ductal Adenocarcinoma Patients with Isolated Lung Metastasis? Cancers 2022;14:2067. [DOI: 10.3390/cancers14092067] [Reference Citation Analysis]
4 Attard JA, Farrugia A, Pathanki A, Roberts KJ, Dasari B, Isaac J, Ma YT, Chatzizacharias NA. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. Pancreas 2020;49:1264-75. [PMID: 33122513 DOI: 10.1097/MPA.0000000000001694] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
6 Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol 2021;12:2475-83. [PMID: 34790408 DOI: 10.21037/jgo-21-119] [Reference Citation Analysis]
7 Park SJ, Kim JH, Joo I, Han JK. Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT. Abdom Radiol (NY) 2021;46:4765-78. [PMID: 34085090 DOI: 10.1007/s00261-021-03127-3] [Reference Citation Analysis]
8 Byun Y, Choi YJ, Han Y, Kang JS, Kim H, Kwon W, Jang JY. Outcomes of 5000 pancreatectomies in Korean single referral center and literature reviews. J Hepatobiliary Pancreat Sci 2021. [PMID: 33636051 DOI: 10.1002/jhbp.933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhou Y, Liao S, You J, Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 2021. [PMID: 34021484 DOI: 10.1007/s13304-021-01089-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ye C, Sadula A, Ren S, Guo X, Yuan M, Yuan C, Xiu D. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol 2020;86:731-40. [PMID: 33047181 DOI: 10.1007/s00280-020-04165-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Belyaev O, Bösch F, Brunner M, Müller-debus CF, Radulova-mauersberger O, Wellner UF, Grützmann R, Keck T, Werner J, Witzigmann H, Uhl W. Von der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie konsentierte Operationsindikationen beim duktalen Pankreasadenokarzinom. Zentralbl Chir 2020;145:354-64. [DOI: 10.1055/a-1161-9501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ishido K, Hakamada K, Kimura N, Miura T, Wakiya T. Essential updates 2018/2019: Current topics in the surgical treatment of pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:7-23. [PMID: 33532676 DOI: 10.1002/ags3.12379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Karunakaran M, Barreto SG. Surgery for pancreatic cancer: current controversies and challenges. Future Oncol 2021. [PMID: 34747183 DOI: 10.2217/fon-2021-0533] [Reference Citation Analysis]
14 Otsuka H, Murakami Y, Uemura K, Kondo N, Nakagawa N, Okada K, Seo S, Takahashi S. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. J Hepatobiliary Pancreat Sci 2020;27:421-8. [PMID: 32219999 DOI: 10.1002/jhbp.737] [Reference Citation Analysis]
15 Flak RV, Fisker RV, Bruun NH, Stender MT, Thorlacius-Ussing O, Petersen LJ. Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer-Results from a Prospective Cohort. Cancers (Basel) 2021;13:2862. [PMID: 34201272 DOI: 10.3390/cancers13122862] [Reference Citation Analysis]
16 Kato H, Horiguchi A, Ito M, Asano Y, Arakawa S. Essential updates 2019/2020: Multimodal treatment of localized pancreatic adenocarcinoma: Current topics and updates in survival outcomes and prognostic factors. Ann Gastroenterol Surg 2021;5:132-51. [PMID: 33860134 DOI: 10.1002/ags3.12427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 De Simoni O, Scarpa M, Tonello M, Pilati P, Tolin F, Spolverato Y, Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E3402. [PMID: 33213022 DOI: 10.3390/cancers12113402] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Oshima M, Okano K, Suto H, Ando Y, Kamada H, Masaki T, Takahashi S, Shibata T, Suzuki Y. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer. BMC Gastroenterol 2020;20:423. [PMID: 33317455 DOI: 10.1186/s12876-020-01566-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kang MJ, Kim SW. Paradigm shift for defining the resectability of pancreatic cancer. Ann Hepatobiliary Pancreat Surg 2021;25:451-5. [PMID: 34845115 DOI: 10.14701/ahbps.2021.25.4.451] [Reference Citation Analysis]
20 Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu JK, Kim YT, Oh DY, Chie EK, Jang JY. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobiliary Pancreat Sci 2021. [PMID: 34581022 DOI: 10.1002/jhbp.1050] [Reference Citation Analysis]
21 Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020;49:904-11. [PMID: 32658074 DOI: 10.1097/MPA.0000000000001592] [Reference Citation Analysis]
22 Schizas D, Koumpoura A, Galari M, Economopoulou P, Vailas M, Sotiropoulou M, Dimitroulis D, Maroulis I, Felekouras E. A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. Per Med 2021;18:613-27. [PMID: 34676789 DOI: 10.2217/pme-2021-0031] [Reference Citation Analysis]
23 Yildiz TA, Köse E, Elliott SL. MATHEMATICAL MODELING OF PANCREATIC CANCER TREATMENT WITH CANCER STEM CELLS. J Biol Syst 2021;29:799-822. [DOI: 10.1142/s0218339021500182] [Reference Citation Analysis]